The role of extracellular vesicles from different origin in the microenvironment of head and neck cancers
Changqing Xie¹², Ning Ji², Zhangui Tang¹*, Jing Li²* and Qianming Chen²

Abstract
The proliferation and metastasis ability of tumors are mediated by the "mutual dialogue" between cells in the tumor microenvironment (TME). Extracellular vesicles (EVs), mainly exosomes and microvesicles, play an important role in achieving intercellular substance transport and information transfer in the TME. Initially considered "garbage dumpsters" and later referred to as "signal boxes", EVs carry "cargo" (proteins, lipids, or nucleic acids) that can redirect the function of a recipient cell. Currently, the molecular mechanisms and clinical applications of EVs in head and neck cancers (HNCs) are still at an early stage and need to be further investigated. In this review, we provide insight into the TME of HNCs, classifying and summarizing EVs derived from different cell types and illuminating their complex signaling networks involved in mediating tumor proliferation, invasion and metastasis, vascular angiogenesis and cancer drug resistance. In addition, we highlight the application of EVs in HNCs, underlining the special pathological and physiological environment of HNCs. Given the concept of precise and individual therapy, nanostructured EVs are equipped with superior characteristics of biocompatibility, low immunogenicity, loadability and modification ability, making these molecules one of the new strategies for HNCs treatment.

Keywords: Tumor microenvironment, Extracellular vesicles, Exosomes Microvesicles, Cell-to-cell communication, Head and neck cancers

Introduction
Head and neck cancers (HNCs) is one of the most common malignant tumors in the world. The head and neck section addresses nonmelanoma skin cancer (NMSCs) of the head and neck as well as those malignancies that arise from the mucosal surfaces of the upper aero-digestive tract (UADT) and salivary glands, thyroid cancers are part of a separate section in the AJCC Cancer Staging Manual, eighth edition [1]. The HNCs described herein will mainly include almost all mucous malignancies of the oral cavity (e.g., tongue, buccal, gingiva, lip, and palate), oropharynx, larynx and nasopharynx [1]. In addition, the jaw, salivary glands, and maxillary sinuses are also included, and more than 90% HNCs are squamous cell carcinomas (SCCs) [2, 3]. Data from the International Agency for Research on Cancer (IARC), based on GLOBOCAN worldwide estimates, show that approximately 600,000 new cancer cases are reported (accounting for approximately 3% to 5% of all malignancies), and 350,000 cancer-related deaths occur (accounting for approximately 4% of the world total) worldwide each year, bringing serious challenges to social and public health [4–6].

Numerous epidemiological studies have reached a consensus that tobacco and alcohol consumption, both of which have synergistic effects, are the major risk factors for HNCs. In high-income countries, 71% and 37% of patients with oral cancer died from smoking and alcohol, respectively, compared with 33% and 14% in low- and
middle-income countries [5, 7, 8]. A growing number of studies have suggested that betel-quid chewing with or without tobacco [9, 10], and human papilloma virus (HPV) infection (HPV16/18) are intimately related to the occurrence of HNCs. These two risk factors may lead to the younger age distribution and the increased rate of females in HNCs in recent years [11].

The treatment of local and early HNCs mainly involves resection with clear 1- to 2-cm margins [3]. In patients with advanced stage cancers and cervical lymph node metastasis, radical surgery combined with radiotherapy/chemotherapy adjunctive therapy is required [2, 3]. The strong invasion, migration and metastasis of HNCs leads to clinical treatment difficulty and poor prognosis. Over the past several decades, although there has been many innovations in HNCs treatment strategies, the overall 5-year survival rate is still only approximately 60% [2, 3, 5, 12]. Consequently, investigating the molecular mechanism and screening precise biomolecular markers of HNCs development is a tremendous challenge and opportunity.

Increasing numbers of studies have demonstrated that the interaction between tumor cells and the tumor microenvironment plays a crucial role in manipulating the tumor immune response, tumor progression and metastasis [13]. The tumor microenvironment has unique heterogeneity and diversity, which not only refers to the homeostatic intracellular environment of tumor cells but also the extracellular stromal cells (for example, fibroblasts, mesenchymal stem cells, various immune cells, vascular endothelial cells, etc.) and multiple tumor-promoting bioactive molecules [14]. Compared to the normal tissue environment, the tumor microenvironment has many different physical and chemical properties, which characterized by low oxygen, low pH and high interstitial pressure [15–18]. Due to this peculiarity, complex network signal communication between cells in the tumor microenvironment is triggered via several growth factors, cytokines, proteolytic enzymes and other active factors and is initially beneficial to tumor cell proliferation, migration, invasion, angiogenesis and radiotherapy/chemotherapy resistance. Among these biological mediators, extracellular vesicles (EVs), which function as information messengers, have gradually attracted the attention of researchers.

**Background of extracellular vesicles (EVs)**

EVs are a subcellular structure of phospholipid bilayers membrane-enclosed vesicles. Numerous studies have shown that the cells of virtually all organisms (from prokaryotes to eukaryotes) can release the EVs to extra-environment in an autocrine or paracrine manner [19]. Initially considered "garbage dumpsters" and later referred to as "signal boxes", the entire history of the development of EVs can be divided into three periods. The first period was in the 1960s. Researchers extracted a precipitate from normal blood by high-speed centrifugation and confirmed that this precipitate, similar to the thromboplastic protein fraction, which is the predecessor of EVs, can reverse coagulation dysfunction [20]. Subsequently, it was further confirmed that activated platelets can release lipid-rich particles, referred to as "platelet dust", which contain platelet factor 3 and can accelerate coagulation [21]. The second period was the 1970s and 1980s. Multiple studies have demonstrated the presence of membrane-like vesicle structures in other solid tissues, physiological fluids, and cell culture supernatants [22–24]. In addition to vesicles that originate directly from membrane shedding, researchers have revealed that vesicle structures are also derived from the intracellular secretion pathway of multivesicular endosomes (MVEs) or multivesicular bodies (MVBs), which are named exosomes [25, 26]. The third period is after the 1990s, during which the cell-cell communication function of EVs has gradually gained value, beginning with a landmark discovery of Epstein-Barr virus (EBV) infected B-cells capable of secreting molecules for the enrichment of major histocompatibility complex (MHC) class II-stimulated CD4+ T lymphocytes involved in the immune response [27, 28]. EVs are rich in lipids, polypeptides, proteins, RNA, DNA and other bioactive substances. EVs could be involved in various physiological and pathological processes, including cell cycle, apoptosis [29], angiogenesis [30], thrombosis formation [31], immune inflammation [32], fibrosis [33], and tumor development [34, 35].

The extraction methods for EVs have been very mature and commercialized [36]. Classical methods widely recognized by academic researchers, include ultracentrifugation [37], gel exclusion chromatography [38], immunoprecipitation [39], high performance liquid chromatography [40], flow cytometry [41], microfluidic chip [42] and other technologies, can acquire different subsets EVs. Western blotting, transmission electron microscopy, dynamic light scattering, and nanoparticle tracking analysis can identify these molecules. However, these methods cannot completely purify specific subpopulations, the products are often enriched with mixed vesicles in which one subgroup is dominant. These vesicles have more or less overlapping or similar particle sizes, morphologies, origins, contents, and functions. At present, the most classical EVs are mainly of two major types: exosomes and microvesicles [43].

**Biogenesis of exosomes**

Exosomes are endosome-derived vesicles with a particle diameter of 30-100 nm (or 150 nm) and are cup- or disc-shaped under electron microscopy [19, 27, 44]. The formation of endosomes is the result of the dynamic
equilibrium of membrane regeneration and degradation [45] (Fig. 1a). The formation of early endosomes originating from membrane retraction accompanied the continuous inward generation and enrichment of intraluminal vesicles (ILVs), which could be consider as exosomes [28]. Early endosomes can evolve into MVEs or MVBs, which ultimately fuse with cell membranes to excrete intrinsic exosomes and other active substances or undergo degradation in lysosomes and autophagosomes [46, 47].

A variety of proteins and molecules are involved in the formation, content assembly and secretion of exosomes. The most explicit mechanism is the endosomal sorting complex required for transport (ESCRT) complex and its associated accessory proteins (ALIX, VPS4, and TSG101) [28, 48]. The general process is as follows. First, the ESCRT complex (0, I, and II) actively recognizes and sequester ubiquitinated proteins on the endosomal membrane and then inward regenerates the buds to form the ILV/exosome structure through membrane remodeling. Finally, ESCRT-III performs a cutting function to free the ILV/exosome [44]. Studies have also confirmed that the formation of exosomes can be independent of the ESCRT pathway. For example, tetraspanins CD63 [49] and lipid metabolism enzymes neutral sphingomyelinase (nSMase) [50] can also induce and assemble exosome contents.

The key protein that regulates the intracellular trafficking of exosomes is the RAB family proteins, which consists of more than 60 GTPases [28]. The diversity of individual RAB binding partner determines the specific vesicle transport route and creates the complexity of membrane trafficking [28, 51]. RAB5 and RAB21 are involved in early endosome transport and mediate endocytosis pathway while RAB7 regulates cargo trafficking from early endosome to late endosome and subsequently to lysosome for degradation [52]. RAB27 is consider as a pivot protein involving in tumor-associated vesicle trafficking and highly expressed in many tumors. In addition, a lot of RAB proteins are associated with exocytic pathway including RAB 3, RAB11, RAB26, RAB27, RAB37, RAB35 and RAB38 [19]. Another vesicle transport route is from trans-Golgi network (TGN) to the plasma membrane, which is mediated by RAB22 and RAB31. Different RAB subtype proteins can selectively regulate the transport of different exosomes and anchor MVBs on the cell membrane [53]. For example: RAB27 regulates the transport and release of exosomes from advanced endosomes rich in CD63, ALIX, TSG101 [54], whereas the release of early nuclear endosomes rich in Wnt, PLP, and TIR is associated with RAB11 and RAB35 [55]. Ultimately, MVBs fuse with the membrane for the release of exosomes into the extracellular environment.
Biogenesis of microvesicles
Compared to exosomes, the biogenesis of microvesicles (ectosomes, microparticles) is relatively simple. These vesicles are formed directly from the budding or shedding of the plasma membrane (PM) and have particle diameters ranging from 50 nm to 10 μm [56]. The biogenesis of PM-derived vesicles are diverse and homologous to the exosomes (Fig. 1b). The crosslinking of membrane surface receptors induces membrane retraction through the ESCRT pathway to form early exosomes that differentiate into exosomes or sprouting to form PM-derived vesicles [28]. In addition, external stress (DNA damage and irradiation), changes in intracellular calcium levels [57], and GTPase ARF6 overexpression also can trigger the release of PM-derived EVs by remodeling the cytoskeleton [58].

Dysregulation of EVs in the tumor microenvironment (TME)
Compared to the normal state, there is a difference between the population and contents of EVs in the pathological microenvironment [59]. When cells exposed to various stress responses (e.g., hypoxia, acidity, and nutritional deficiencies), the biogenesis, content sorting and release of the EVs could change, and these molecules become the active factors that initiate the signaling pathway. For example, GTPase RAB22A regulates the secretion of extracellular vesicles depending on the hypoxia-inducible factors (HIFs) in a hypoxic environment [60]. Additionally, fat production-related pathways could be activate, and this abnormal fat metabolism is conducive to the formation and release of cancer cell exosomes [61]. However, triglyceride accumulation in exosomes results in an "energy storehouse", which can influence epithelial remodeling and connectivity functions [62, 63], and therefore promote the proliferation and infiltration of cancer cells. Hypoxic-EVs contain various oncogenic molecules that participate in the blood vessel formation, cell metastasis and other signaling pathways that ultimately affect the development of cancer [62, 64, 65]. Moreover, under the stimulation of inflammatory factors, such as TNF-α, IL-1β, IFN-γ and LPS, endothelial cells can upregulate exosome secretion in a concentration-dependent manner [66]. Proteomic and gene expression analyses have shown that superoxide dismutase, VEGF, immune activation factor, and NF-kB signaling molecules were overexpressed in EVs compared to normal endothelial cells [66, 67].

In summary, the mechanism of EVs produced by different cells and the characteristics of EVs produced under physiological and pathological conditions are different. Based on the specificity anatomy of the head and neck (e.g., the initial segment of the digestive tract and respiratory tract, the coexisting hard tissue and mucosal soft tissue, and the dynamic microenvironment of saliva and plaque microbes), EVs in the HNCs microenvironment have unique characteristics. Sequencing or proteomic analysis data could show the specificity results of HNCs-derived EVs (Table 1).

Function of EVs in head and neck cancers
Traditionally, tumor cells play a central leading role in the TME. However, in recent decades, studies have revealed that the successful proliferation and metastasis of cancer are inseparable from the "mutual dialogue" between tumor cells and stroma (Fig. 2 and Table 2).

EVs in cancer-to-cancer communication
Heterogenous tumor cells can increase the motility and angiogenic activity of surrounding tumor cells by secreting EVs and creating a premetastatic microenvironment [59, 68], which is one of the key mechanisms of tumor recurrence and metastasis. By artificially mimicking the OSCC TME (arranging tumor cells in a three-dimensional myoma or collagen gel model), it was found that tumor-derived exosomes play an important role in regulating tumor epithelial morphology and function [69]. Exosomes could promote the formation of tumor epithelial islands and of the expression of interstitial cell characteristics, such as upregulating N-cadherin, downregulating E-cadherin and GLI-1, and eventually promoting the epithelial-mesenchymal transition (EMT) [70, 71]. Shinya Sento et al. demonstrated that OSCC-derived exosomes can self-uptake or become absorbed by surrounding tumor cells and then accelerate cell proliferation and invasion by activating AKT, MAPK/ERK, and JNK signaling pathways [72].

However, it is unclear what kind of active molecules in HNC-derived EVs play a role in the regulation of tumor progression. Proteomic analyses revealed that OSCC-derived EVs contain a series of tumor-associated proteins, including TRAP1, EGFR, HSP-90, and MMP-13. These proteins are significantly associated with the clinical stage and prognosis of OSCC patients and may serve as potential biomakers for metastatic phenotype and treatment of OSCC [73–75]. LMP1-positive exosomes and exosomal HIF-1α can also increase motility and invasiveness of HNCs via the EMT [76], Andrew M. Overmiller et al. found that HNC-derived exosomes are rich in Dsg-2 [77]. The overexpression of Dsg-2 may promote tumor progression by degrading caveolins and matrix metalloproteinases could enhance EVs biogenesis and mitogenic effects [77–79].

Noncoding RNAs in HNCs-derived EVs are involved in the regulation of tumor progression [80, 81]. These noncoding RNAs may play an important function in promoting tumor development or inhibiting tumor progression. Hypoxia-induced OSCC exosomes can increase cancer cell migration and infiltration capacity. MiRNA-21 is significantly upregulated in hypoxic-derived OSCC
exosomes, which is dependent on HIF-1α and HIF-2α pathways. MiRNA-21-enriched exosomes increase the expression of Snail and Vimentin proteins and downregulate E-cadherin levels in tumor cells, suggesting that OSCC can create a niche for distant transfer through the EMT [75, 82]. Highly metastatic and invasion oral cancer cells can transport exosome-derived miRNA-1246 and miRNA-200c-3p to the parental OSCC, which could target and bind to DENN/MADD Domain Containing 2D (DENND2D) and CHD9/WRN to promote tumor cell proliferation, metastasis, and invasion [83, 84]. More interestingly, the expression of miRNAs in EVs is a “selective” but not random process. OSCC cell lines can selectively package and discard miR-142-3p in exosomes. This process can activate the TGFBR1 pathway, which promotes endothelial cell angiogenesis and maintains the malignant states of tumor cells [85, 86].

Drug resistance is the main reason for the failure of chemotherapy in cancer patients. Interestingly, the exposure of head and neck tumor cells to some chemotherapy drugs (cisplatin, doxorubicin, and ROS-associated drugs) can lead to an imbalance of oncogenic contents in EVs and reduce the anti-proliferation and anti-metastatic effect of chemotherapy drugs [87, 88]. High chemoresistance OSCC cells can enhance drug resistance and reduce DNA damage by encapsulating miRNA-21 in exosomes and transporting it to target PTEN and PDCD4 [87, 89]. Radiation stress could increase the secretion of exosomes, which could absorbed by unexposed tumor cells, hence increasing tumor cell migration and radiotherapy tolerance by provoking AKT-related signaling pathways or participating the repair of DNA double-strand break [90, 91].

**EVs in cancer-to-stroma communication**

Tumor cell-derived extracellular vesicles, in addition to their uptake, can also transported to tumor stromal cells in a paracrine manner. Illumination of the mechanism of tumor-derived exosomes in mediating cell-cell communication could definitely provide a new perspective for the development of tumors.

**Table 1** Sequencing or array and proteomic analysis datas results from different samples of HNCs-derived Evs

| Sample source of EVs | Extract method of EVs | EVs marks | Sequencing method or array | Proteomic analysis | Tumor cells | Reference |
|----------------------|-----------------------|-----------|---------------------------|-------------------|-------------|-----------|
| Oral Squamous Cell Carcinoma (OSCC) cell line: HSC-3, SQUU-A, Cal-27, SCC-4, SCC-9, SCC-25, H413, HOC313. Head and Neck cancers (HNCs) cell lines: SQUU, BHY, Tu167, HN60, SCC0299, Detroit 562, FaDu, TW03, C666-1. AFs: adjacent tissue fibroblasts. DOK: oral dysplastic cell line. NP69, NP460: immortalized nasopharyngeal epithelial cells | | | | | | |
Cancer-to-endothelial cells

Folkman proposed the concept of "tumor growth depends on angiogenesis" as early as the 1970s [92]. Tumor angiogenesis activity has important value for histopathological grading, radiotherapy evaluation and prognosis. Therefore, patients undergoing surgery, radiotherapy and chemotherapy combined with tumor vascular blocking could effectively prevent the proliferation and metastasis of tumors. At present, studies on the mechanism of tumor angiogenesis have mainly focused on a variety of pro-angiogenic factors (e.g., VEGF, FGF, PDGF) [93], but EVs also play an important role in the regulation of tumor angiogenesis [94].

The EVs derived from HNC cell can promote the malignant phenotype of tumor cells by delivering exosomal PFKFB3, Shh and other angiogenic proteins and activating the relevant model pathway to induce endothelial proliferation and tube formation [95, 96]. In addition, nasopharyngeal carcinoma (NPC) cell-derived exosomal miRNA-23a directly target the TSGA10 region to promote endothelial cell proliferation, migration and tube formation [97]. Recent studies have shown that epiregulin-, MMP-13-, ICAM-1- or TSP-1-enriched exosomes could strengthen the release of vascular endothelial growth factors (VEGF-A, FGF-2, IL-8) and then downregulate junction-related proteins (claudins and ZO-1) that promote tumor angiogenesis and vascular permeability, becoming a potential passway system for distant metastasis of tumor cells [70, 71, 73, 98].

Cancer-to-fibroblast cells

Cancer-associated fibroblasts (CAFs) are the major stromal cells in the TME [99]. Under physiological conditions, fibroblasts secrete a variety of factors (collagens, fibronectin, etc.) that play a role in maintaining the homeostasis of the extracellular matrix (ECM). In tumor microenvironment, fibroblasts could be activated by tumor-associated chemokines (e.g., TGF-β, IL-6, and...
Table 2 The function of different cell-derived EVs in the microenvironment of HNCs

| Originator of EVs | Recipient of EVs | Type of EVs | Biomolecular marker | Function | References |
|------------------|------------------|-------------|--------------------|----------|------------|
| Exosome          | Epithelial      | miRNA       | EGFR               | Induce EGFR expression and enhance tumor cell proliferation | Tsyganov et al. 2017 |
| Exosome          | Pericytes, smooth muscle cells, and fibroblasts | miRNA     | IDO                 | Promote tumor angiogenesis and immunosuppression | Seree et al. 2016 |
| Exosome and Microvesicle | miRNA   | Human-derived vessels and stromal cells | M2       | Inhibit cancer cell proliferation and enhance tumor cell migration | Ong et al. 2018 |
| Exosome          | Macrophages     | miRNA       | TAM                | Induce the M2 phenotype and increase tumor cell motility and invasion | Zhan et al. 2014, Mathew et al. 2016 |
| Exosome          | Cancer cell     | miRNA       | PD-L1              | Increase tumor cell survival and resistance to immunotherapy | Age et al. 2014 |
| Exosome          | Cancer cell     | RNAi         | CRISPR-Cas9         | Enhance tumor cell sensitivity to DNA damage and apoptosis | Vass et al. 2018 |
| Exosome          | Cancer cell     | RNAi         | siRNA              | Induce tumor cell apoptosis and enhance tumor cell sensitivity to chemotherapy | Loh et al. 2014, Lee et al. 2017 |
| Exosome          | Cancer cell     | RNAi         | siRNA              | Induce tumor cell apoptosis and enhance tumor cell sensitivity to chemotherapy | Sim et al. 2018 |
| Exosome          | Cancer cell     | RNAi         | siRNA              | Enhance tumor cell sensitivity to DNA damage and apoptosis | Danilchenko et al. 2017, Mochalska et al. 2018 |
| Exosome          | Cancer cell     | RNAi         | siRNA              | Induce tumor cell apoptosis and enhance tumor cell sensitivity to chemotherapy | Gil et al. 2017 |
| Exosome          | Cancer cell     | RNAi         | siRNA              | Induce tumor cell apoptosis and enhance tumor cell sensitivity to chemotherapy | Kim et al. 2017 |
| Exosome          | Cancer cell     | RNAi         | siRNA              | Induce tumor cell apoptosis and enhance tumor cell sensitivity to chemotherapy | Bae et al. 2018 |
| Exosome          | Cancer cell     | RNAi         | siRNA              | Induce tumor cell apoptosis and enhance tumor cell sensitivity to chemotherapy | Park et al. 2018 |
| Exosome          | Fibroblasts     | RNAi         | siRNA              | Induce tumor cell apoptosis and enhance tumor cell sensitivity to chemotherapy | Vass et al. 2018 |
| Exosome          | Stromal cells   | RNAi         | siRNA              | Induce tumor cell apoptosis and enhance tumor cell sensitivity to chemotherapy | Han et al. 2018 |
| Exosome          | Macrophages     | RNAi         | siRNA              | Induce tumor cell apoptosis and enhance tumor cell sensitivity to chemotherapy | Wang et al. 2019 |

**Note:** This table summarizes the function of different cell-derived EVs in the microenvironment of head and neck cancer (HNC) cells.
IL-8) and subsequently converted to CAFs. Tumor cell-derived exosomes can also assist in fibroblast translation to CAFs, resulting in a premetastatic microenvironment [100, 101]. Oral tumor cells can package their "undesirable" or "unhealthy" substances in EVs to relieve the damage caused by external environmental stimuli and simultaneously promote high expression of α-SMA and Twist by fibroblasts, suggesting that exosomes may mediate the EMT and regulate the conversion of fibroblasts into CAFs [79]. In order to adapt the hypoxia and hypo-nutrient conditions, tumor cells can achieve metabolic reprogramming by regulating the release EVs [102]. Hypoxia induces oral tumor cells or CAFs to secrete caveolin-1, trafficking by extracellular vesicles, which as a direct transcriptional target of HIF-1α and HIF-2α. On the one hand, EVs derived from tumor cells cause a crisis on oxidative stress of the TME. On the other hand, caveolin-1-null CAFs, induced by exocytosis or other pathways, provide multiple metabolic substrates (e.g., lactate, pyruvate, ketone) for tumor tissues. In brief, EVs may be involved in the construction of pseudo-hypoxic conditions of the TME and contribute to tumor development. Moreover, EVs from HNSCC encapsulate a large number of mitogenic proteins that regulate the proliferation of fibroblasts by various types of pathways such as EGFR, AKT, and ERK1/2, in a concentration-dependent manner [77].

**Cancer-to-immune cell**

The effective amplification and metastasis of cancer cannot be separated from the immune escape ability of cancer cell or treatment-mediated immune surveillance. Tumor cell-derived EVs are indispensable targets in the complex network of tumor immunity [103]. Tumor cell-derived EVs can suppress immune function, promote the differentiation of regulatory T cells and tumor-associated macrophages, and even replace tumor cells with immune cell attack to assist tumor cell immune tolerance and immune escape [104–106].

HNC-derived exosomes can prevent the proliferation of T lymphocytes and inhibit their differentiation into Th-1 and Th-17 cell subtypes and promote their conversion to Treg lymphocytes and myeloid-derived suppressor cells (MDSCs) [107]. Compared to other T-cell subtypes, Tregs are more susceptible to regulation by EVs derived from CAFs or their supernatants, leading to the increased production of immunosuppressive adenosine [108]. HNC-derived exosomes enriched galectin-1 mediate the downregulation of STAT-1/-3 phosphorylation and upregulation of STAT-5 phosphorylation via the MAPK/ERK pathway or decrease expression of CD27/28-induced CD8+ T cells, displaying a suppressor phenotype [109]. Similar research proves that hypoxia inducing the upregulation of exosomal miRNA-24-3p in HNCs, which can repress FGF-11 to inhibit phosphorylation of the ERK and STAT proteins of T cell [110]. HNC-derived EVs function by endocytosis and activate T-cell surface receptors to regulate the transcription of immune-related genes. The surface proteins Fas-L and MHC-I of HNC-derived EVs mediate the apoptosis of CD8+ T lymphocytes [111–114]. The effects of oral tumor cell-derived exosomes on macrophages are uncertain. These vesicles can induce the polarization of THP-1 cell to tumor-associated macrophages M2 but have no significant effect on primary human macrophages [115]. Under certain conditions, EVs can also mediated antitumor immune responses. HNC-derived exosomes can upregulation NF-κB-activating NAPI expression in NK cells, activate the expression and phosphorylation of IRF-3, and release multiple antitumor inflammatory factors (IFNs, CD40/80/86, and CXCILs) [116]. Overall, HNC-derived EVs mediate the bidirectional regulation of tumor immunity, suggesting that future immunotherapy may be based on the tumor microenvironment or individualized treatment of circulating EVs.

**EVs in stroma-to-cancer communication**

The transfer of EVs between tumor cells and stroma cells is not unidirectional but rather occurs through dynamic bidirectional and multidirectional complex signal network (Fig. 3). Stromal cells are not a passive bystander in the development of tumors. Practically, stromal-derived EVs play a critical role in the reconstruction of ECM [59], dictate local and distant metastasis [117] and regulation of drug resistance in tumor cells [118].

TGFβ type II receptor (TβRII) in CAFs-derived exosomes can reactivates the TGF-β signaling pathway in OSCC cells, which is closely related to tumor heterogeneity and tumor progression [119]. The coculture of oral tumor cells with CAFs or their supernatants can drive the transformation of tumor cell cycle to S and G2-M phases, downregulate the expression of E-caderin, and promote the invasion and migration of OSCC cells through EMT [120]. Protein profiling revealed that the high expression of MFAP5, a protein component of extracellular microfibrils, in CAFs-derived exosomes triggers the activation of MAPK and AKT signaling pathways and promotes the proliferation and metastasis of OSCC cells [121] (Fig. 3a). In addition, FGF-19 is highly expressed in mesenchymal stem cell-derived exosomes (Fig. 3b), which can induce the EMT through activation of the NPC cell FGF-19/FGFR-4 signaling pathway and promote tumor cell progression [122].

**EVs derived from other sources**

The head and neck are located in the beginning of the digestive and respiratory tract. Distinctive anatomical
location makes the malignant tumor originating in this area to the pathogenic microbial environment. In recently decades, the ratio of HPV-positive oropharyngeal cancer (OPC) [3, 11] and EBV-infection NPC in HNC patients has increased (Fig. 3c).

Several studies have verified that HPV-positive cancer cells can dictate the expression levels of tumor genes and proteins in EVs to exert proliferative, anti-apoptotic and anti-senescent effects on surrounding cells [123, 124]. The persistent expression of E6/E7 protein in HPV-positive cancer cells can alter the miRNA pool in intracellular and exosomes; for example, the upregulated miRNA-17 family can inhibit P53/P21 expression levels and regulate tumor cell proliferation [125]. HPV-associated oropharyngeal cancer-derived exosomes packing MUC16, SIRPA and HPV-16-E7 proteins enhance the invasion of epithelial cells via the EMT [126].

EBV can hijack cancer-derived EV production to regulate cell-to-cell communication and package onco-proteins or virus-coding miRNAs, such as E6/E7, MUC16, LMP1, EGFR, and miRNA-BART, which modulate the TME and promote tumor development. EVs from the saliva d and circulating blood e of patients with HNCs can be used not only as potential biomarkers to reflect the clinical stage of tumor pathology but also as carriers of active molecules involved in tumorigenesis.

**Fig. 3** Different sources of EVs in the cancer-to-stroma communication network. Stromal cells are not bystanders in the development of tumors. 

- **A** Cancer-associated fibroblast (CAF)-derived EVs loaded with TβRII and MFAP5, which reactivate the TGF-β signaling pathway, trigger the activation of MAPK and AKT signaling pathways and promote the proliferation and metastasis of OSCC. 
- **B** Mesenchymal stem cell (MSC)-derived exosomal FGF-19 induces the EMT via the FGF-19/FGFR-4 signaling pathway and promotes tumor cell progression. 
- **C** HPV and EBV can hijack cancer-derived EV production to regulate cell-to-cell communication and package onco-proteins or virus-coding miRNAs, such as E6/E7, MUC16, LMP1, EGFR, and miRNA-BART, which modulate the TME and promote tumor development. EVs from the saliva d and circulating blood e of patients with HNCs can be used not only as potential biomarkers to reflect the clinical stage of tumor pathology but also as carriers of active molecules involved in tumorigenesis.

**Potential application of EVs in head and neck cancers**

**Application in the screening and diagnosis of head and neck cancers**

As a tool for liquid biopsy, EVs have unique advantages over circulating tumor DNA (ctDNA) and Circulating Tumor Cells (CTCs) [133, 134]. EVs highly reserve the original source of cellular biological information and easier to enrich and acquire [81]. More importantly, the protective effect of the double-layered membrane structure of EVs overcomes the problem of easy degradation.
of nucleic acids. In recent years, technology for search potential biomarkers of oral tumors in saliva EVs (Fig. 3d) and circulating EVs (Fig. 3e) has become increasingly mature [135]. Additionally, in the tumor microenvironment, either donor or recipient cells of EVs in the TME undoubtedly undergo genetic and epigenetic changes. Although primary tumor sample is standard starting material to perform genetic analyses, limiting factor is the obtained DNA cannot indicate genetic and epigenetic changes, such as acquired resistance to EGFR inhibitor, which is a major issue worldwide. Liquid biopsy is becoming a common alternative approach to perform molecular analyses, since it is less invasive than tumor biopsy and it is easily repeatable. cfDNA in EVs could be used to evaluate genetic and epigenetic changes in tumor before treatment but also to monitor clinical responses.

Compared with other solid tumors, in addition to substance exchange with circulating body fluids (blood, lymph), oral tumors also undergo saliva (including gingival crevicular fluid) erosion and biological effects. In oral tumor microenvironment, tumor-associated biomolecules can enter the saliva through blood circulation or directly through saliva components [136, 137]. Saliva components similar to blood, containing a large number of proteins and genetic material [138–141]. Previously, saliva was mainly diagnostic for HNCs (especially oral cancer), and an increasing number of experiments confirmed that saliva components can also be used to monitor and screen other tumors, such as pancreatic cancer [142], lung cancer [143], breast cancer [144]. The concentration of saliva-derived exosomes in oral cancer patients significantly increased compared to that in healthy populations and displays irregular morphologies and larger particle sizes [140, 145–147]. OSCC-derived saliva exosomes contain a variety of tumor-associated proteins involved in multiple signaling pathways, including tumor immune responses, cell proliferation, and metal transport [148]. Recent studies have shown that miRNA-512-3p and miRNA-412-3p were highly expressed in saliva exosomes of OSCC patients. Receiver operating characteristic curves show that these two miRNAs have a good discrimination power for OSCC diagnosis and may serve as potential candidate biomarker [149]. Oral cancer-derived salivary exosomes significant increase in the expression of CD63 and decrease in the expression of CD9 and CD81, which could serve as an indicator for cancer, even in the early stages of the disease [147]. Therefore, salivary fluid diagnosis has the virtues of convenient sampling, real-time performance, and noninvasiveness. Therefore, this technique has unique advantages in the early diagnosis of tumors, the detection of tumor progression and drug treatment evaluation [80, 150, 151].

The obvious upregulation of circulating EVs population in oral cancer patients positively correlated with IL-6 and TNF-α in tumor tissues. Tumor-derived microparticles can enhance the coagulation function of microparticles free plasma, which may promote venous thrombosis and involved in tumorigenesis [152]. High levels of miRNA-21 and lncRNA (HOTAIR) in serum-derived exosomes can reflect the clinical stage and lymph node metastasis of laryngeal squamous cell carcinoma, and evaluation of the expression of both molecules can increase diagnostic efficiency and accuracy [153]. A recent study showed that the plasma-derived exosomes in HNCs patients promote tumor cell proliferation, migration and invasion via the EMT. However, after photodynamic therapy, the patient plasma-derived exosomes can reverse this process and suppress malignant tumor cell characterization [154]. Plasma-derived exosomes from HNCs can also induce immune disorders to regulate the tumor microenvironment [155].

Application in prognostic risk evaluation

The prognostic evaluation of patients with metastatic tumors, including HNCs, is undoubtedly important for predicting tumor treatment outcomes, reducing recurrence and mortality, and prolonging survival. The inclusion of EVs as a prognostic factor for HNCs may become a trend of near future. Some EV-derived proteins (caveolin-1, HIF-1α, HSP-90, and MMP-2/9/13) shown closely related to the survival rate of patients with HNCs [74, 75, 79]. The level of extracellular vesicles in the serum may related to the immune function of patients, which could also indicate a poor prognosis for HNCs [112]. With the continuous updating and deepening of research, EV-associated DNA, protein, noncoding RNA, etc., expected to become useful for prognostic monitoring for HNCs, providing an effective basis for precise treatment.

Application in therapy strategy

As a natural intercellular information carrier, EVs have great application potential in the field of tumor therapy with its nanolevel molecular structure, unique host fingerprint, and properties of good biocompatibility [156]. Currently, the application of extracellular vesicles in clinical treatment can divided into the following areas. First, direct targeting of EV therapy prevents absorption by directly inhibiting the synthesis and secretion of tumor-associated EVs. However, such aggressive measures may produce side effects in patients, thus further investigations with larger clinical cohorts are required prior to EV therapy in the future. Second, EV-based immunization vaccines, involving the isolation and purification of autoimmune cell-derived EVs from tumor
patients and antigen modification for subsequent return to the patient, can activate the ability of the immune system to kill tumor cells [157]. Third, an EV-based vector for cancer treatment drugs attributed to the low immunogenicity and stability of EVs [158]. Efficient and versatile EV anti-tumor delivery can circumvent the physiological barrier system to achieve the targeted treatment of drugs. Last, EV-based regenerative treatment is a research hotspot based on the use of EVs to solve the problem of stem cell survival and reduction in treatment [159]. Some of these treatments have entered the clinical trial period. Unfortunately, there is no clear report on the use of EVs in the treatment of HNCs. We firmly believe that the application of EVs may be a solid supplement to the treatment of HNCs and should encourage further studies in this field.

Conclusions
In summary, EV research is an emerging field that has been rapidly developing and has made some progress. However, the explicit molecular mechanism of EV biogenesis, content loading, intracellular and extracellular transport, and ultimately the regulation of disease progression has not yet explained. EVs are like a "double-edged sword" and have a close relationship with HNCs. On the one hand, EVs, as "alliances" of cancer, can promote the proliferation of cancer cells, assist the escape of cancer cells from the immune system or drug killing, and create a suitable microenvironment for the metastasis of cancer, which plays an important role in the development and progression of cancer. On the other hand, facilitating the occurrence of cancer exposes the existence of cancer and has become an effective means for the diagnosis and treatment of this disease. Currently, there is a debate about the definition of EVs and classification of subtypes and lack of standardization and unification of extraction techniques, which is a tricky issue for studies of EVs. With the advancement of precise and individual treatment, the use of EVs to establish the early screening and diagnosis of head and neck cancers enhance the evaluation of the prognosis and treatment effect, and promote the development of new anti-tumor drugs will be the aims of future exploration.

Abbreviations
AJCC: American Joint Committee on Cancer; AKT: AKT serine/threonine kinase; AUX: Apoptosis-linked gene 2-interacting protein X; ARF6: ADP ribosylation factor 6; CAFs: Cancer-associated fibroblasts; CHD9: Chromodomain helicase DNA binding protein 9; CTCs: Circulating tumor cells; ctDNA: Circulating tumor DNA; CXCLs: Chemokine (C-X-C motif) ligand; DENND2D: DENN/MADD Domain Containing 2D; Dsg-2: C-terminal fragment of desmoglein 2; EBV: Epstein-Barr virus; ECM: Extracellular matrix; EGFR: Epidermal growth factor receptor; EMT: Epithelial-mesenchymal transition; ERK: Extracellular regulated mitogen-activated protein kinase; ESCRT: Sorting complex required for transport; EVs: Extracellular vesicles; Fas/L: Fas ligand; FGF: Fibroblast growth factor; FGF-11: Fibroblast growth factor 11; FGF-19: Fibroblast growth factor 19; FGF-2: Fibroblast growth factor 2; FGF-4: Fibroblast growth factor 4; G1L1: G1 family zinc finger 1; HIF-1α: Hypoxia inducible factor 1 subunit alpha; HIF-2α: Hypoxia inducible factor 2 subunit alpha; HIFs: Hypoxia-inducible factors; HNCs: Head and neck cancers; HPV: Human papilloma virus; HSP-90: Heat shock protein 90; HSPs: Heat shock proteins; IARC: International Agency for Research on Cancer; ICAM-1: Intercellular adhesion molecule 1; IFNs: Interferons; IFN-γ: Interferon gamma; IL-1β: Interleukin 1 beta; IL-6: Interleukin-6; IL-8: Interleukin-8; ILVs: Intraluminal vesicles; IRF-3: Interferon regulatory factor 3; JNK: c-Jun N-terminal kinase; LMP1: Latent membrane protein; LPS: Lipopolysaccharides; MAPK: Mitogen-activated protein kinase; MOSCs: Myeloid-derived suppressor cells; MAFPs: Microfilibril associated protein 5; MHC: Major histocompatibility complex; MMP-2/9/13: Matrix metalloproteinase 2/9/13; MMPs: Matrix metalloproteinases; MUC16: Mucin 16, cell surface associated; MVs: Multivesicular bodies; MVEs: Multivesicular endosomes; NAP1: Kinase-associated protein 1; nSMase neutral sphingomyelinase; NF-κB: Nuclear factor kappa B; NPC: Nasopharyngeal carcinoma; OPC: Olfactory neuroepithelial cell; OSCC: Oral squamous cell carcinoma; PDCD4: Programmed cell death 4; PDGF: Fibroblast growth factor; PKF83: 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3; PDK3: Phosphoinositide-3-kinase; PLP: Proteolipid protein; PM: Plasma membrane; PTEN: Phosphatase and tensin homolog; Rab: Ras-related protein; RAB11: Ras-related protein 11; RAB22A: Ras-related protein 22A; RAB27: Ras-related protein 27; RAB35: Ras-related protein 35; ROS: Reactive oxygen species; SCCs: Squamous cell carcinomas; Shh: Sonic hedgehog; SIRPA: Signal regulatory protein alpha; STAT: Signal transducer and activator of transcription; STAT-1: Signal transducer and activator of transcription 1; STAT-3: Signal transducer and activator of transcription 3; STAT-5: Signal transducer and activator of transcription 5; TLR: Transferin receptor; TNFR1: Transforming growth factor beta receptor 1; TGF-β: Transforming growth factor beta; TNM: Tumor-Node-Metastasis; TME: Tumor microenvironment; TGF-α: Tumor necrosis factor alpha; TRAP1: TNF receptor associated protein 1; TSG101: Tumor susceptibility 101; TSGA10: Testis specific 10; TSP-1: Tumor suppressor region 1; TLR8: Transforming growth factor beta receptor II; UCH-L1: Ubiquitin C-terminal hydrolase L1; VEGF: Vascular endothelial growth factor; VEGF-α: Vascular endothelial growth factor A; VP54: Vacular protein sorting 4 homolog; WRN: Werner syndrome RecQ like helicase; ZO-1: Tight junction protein 1; α-SM: Actin, alpha 2, smooth muscle, aorta

Acknowledgement
None.

Funding
This work was supported by grand from National Natural Science Foundation of China (81872211, 81672675, 81671003, 81621062, 81520108009), 111 Project of MOE (B14038) China.

Availability of data and materials
Not applicable.

Authors’ contributions
JL and QMC designed the manuscript, COX was a major contributor in writing the manuscript, COX and NJ drew the figures and tables, JL and QMC mainly revised the manuscript, QMC, JL and ZGT participated in the design of the review and made some revisions of the review. All the authors read and approved the final version of the review.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Xie et al. Molecular Cancer  
(2019) 18:83

Received: 26 October 2018  Accepted: 25 February 2019

Published online: 06 April 2019

References

1. Lydiatt WM, Patel SG, O'Sullivan B, Brandwein MS, Ridge JA, Migliacci JC, Loomis AM, Shah JP. Head and Neck cancers—major changes in the American Joint Committee on cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(2):122–37.

2. Neville BW, Day TA. Oral cancer and precancerous lesions. CA Cancer J Clin. 2002;52(4):195–215.

3. Chi AC, Day TA, Neville BW. Oral cavity and oropharyngeal squamous cell carcinoma—an update. CA Cancer J Clin. 2015;65(5):401–21.

4. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.

5. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.

6. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.

7. Danazi G, Vander Hoom S, Lopez AD, Murray CJL, Ezzati M. Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. The Lancet. 2005;366(9994):1784–93.

8. Blot WJ, McLaughlin JK, Winn DM, Austin DF, Greenberg RS, Preston-Martin S, Wynder EL. Incidence Rates for Oral Cavity and Oropharyngeal Cancers. J Clin Oncol. 1982;10(12):2200–3.

9. Epstein JB, Thariat J, Bensadoun RJ, Barasch A, Murphy BA, Kolnick L, Madathil SA, Rousseau M-C, Wynant W, Schlecht NF, Netuveli G, Franco EL, Chaturvedi AK, Anderson WF, Lortet-Tieulent J, Curado MP, Ferlay J, Franceschi S, Loomis AM, Shah JP. Head and Neck cancers—major changes in the American Joint Committee on cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(2):122–37.

25. Harding C, Heuser J, Stahl P. Receptor-mediated endocytosis of transferrin. Science. 1981;212(4497):923.

26. Raposo G, Nijman HW, Stoorvogel W, Lendekederk R, Harding C, Melief CJW, Geuze HJ. B lymphocytes secrete antigen-presenting vesicles. J Exp Med. 1996;183(3):1161–72.

27. Colombo M, Raposo G, Thery C. Bio-generation, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol. 2014;30:255–89.

28. Takeuchi M, Okada R, Takahashi A, Veyra Chen D, Watanabe S, Hara E. Small extracellular vesicles secreted from senescent cells promote cancer cell proliferation through EphA2. Nat Commun. 2017;8:15729.

29. Song W, Yan D, Wei T, Liu Q, Zhou X, Liu J. Tumor-derived extracellular vesicles in angiogenesis. Biomed Pharmacother. 2018;102:203–8.

30. Hell L, Wigrich L, AY C, Spittler A, Schwames M, alma B, Pabinger I, Alveogt P, Thaler J. Procoagulant extracellular vesicles in anamnestic fluid. Transf Res. 2017;84:12–9.e11.

31. Turnip D, Truchetet M-E, Faustin B, Augusto J-F, Contin-Bordes C, Brisson A, Blanco P, Duffau P. Role of extracellular vesicles in autoimmune diseases. Autoimmun Rev. 2016;15(2):174–8.

32. Chen W, Yan Y, Sung C, Ding Y, Du T. Microvesicles derived from human Wharton’s jelly mesenchymal stem cells ameliorate ischemia-reperfusion-induced renal fibrosis by releasing from G2/M cell cycle arrest. Biochem J. 2017;474(24):4207–18.

33. Kamerkar S, LeBluex VS, Sugimoto H, Yang S, Ruivo CF, Melo SA, Lee JJ, Kalluri R. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature. 2017;546(7659):498–503.

34. Zhang L, Zhang S, Yao J, Lowey FJ, Zhang Q, Huang WC, Li P, Li M, Wang X, Zhang C, et al. Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth. Nature. 2015;527(7576):100–4.

35. Shao H, Im H, Castro CM, Breakefield X, Weissleder R, Lee H. New Technologies for Analysis of Extracellular Vesicles. Chem Rev. 2018;118(4):1917–50.

36. Thery C, Amigorena S, Raposo G, Clayton A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol. 2006;33(22).

37. Mo EA, Goumans M-J, Doevendans PA, Sluijter JPG, Vader P. Higher functionality of extracellular vesicles isolated using size-exclusion chromatography compared to ultracentrifugation. Nanomed: Nanotechnol Biol Med. 2017;13(6):2061–5.

38. Heinzelman P. Magnetic Particle-Based Immunoprecipitation of Nanoscale Extracellular Vesicles from Blood. Methods Mol Biol. 2017;1742:1–20.

39. Huang T, He J. Characterization of Extracellular Vesicles by Size-Exclusion High-Performance Liquid Chromatography (HPLC). Methods Mol Biol. 1667;2017:191–9.

40. Wiklander O, Bostancioglu R, Welsh J, Zicker A, Murke F, Corso G, Feldlin U, Hagey D, Evertsson B, Liang X, et al. Systematic Methodological Evaluation of a Multiplex Bead-Based Flow Cytometry Assay for Detection of Extracellular Vesicle Surface Signatures. Front Immunol. 2018;9:1326.

41. Gholizadeh S, Shehata Draz M, Zarghooni M, Sanati-Nezhad A, Ghavami S, Shafiee H, Akbari M. Microfluidic approaches for isolation, detection, and characterization of extracellular vesicles: Current status and future directions. Biosens Bioelectron. 2017;91:588–605.

42. Yanez-Mo M, Slajander PR, Andreu Z, Zavec AB, Borras FE, Buza E, Buza K, Casal E, Cappello F, Carvalho J, et al. Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles. 2015;4:27066.

43. Thery C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nat Rev Immunol. 2002;2(8):569–79.

44. Klimperman J, Raposo G. The complex ultrastructure of the endolysosomal system. Cold Spring Harb Perspect Biol. 2014;6(10):a016657.

45. Villarroya-Beltri C, Baixauli F, Mittelbrunn M, Fernandez-Delgado I, Tornalla D, Monero-Gonzalo O, Baldarsta S, Enrich C, Guerra S, Sanchez-Madrid F. ISGylation controls exosome secretion by promoting lysosomal degradation of MVB proteins. Nat Commun. 2016;7:13588.

46. Belbeis M, Smith MJ, Pegtel DM, Baglio SR. Biogenesis and function of extracellular vesicles in cancer. Pharmacol Ther. 2018;188:1–11.

47. Hanson PI, Cashikar A. Multivesicular body morphogenesis. Annu Rev Dev Biol. 2012;28:337–62.
49. van Niel G, Chemin S, Semoos S, Romani M, Rochlin L, Safiq P, Marks MS, Rubinstein E, Raposo G. The tetraspanin CD63 regulates ESCRT-independent and dependent exosomal sorting during melanogenesis. Dev Cell. 2012;114(6):708–21.

50. Trlivačov K, Hui C, Chantaa S, Rajendran L, Wenzel D, Wieland F, Schwippe P, Blegger B, Simons M. Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science. 2008;319(5867):1244–7.

51. Fukuda M. Regulation of secretory vesicle traffic by Rab small GTPases. Cell. 2007;130(6):1039–51.

52. Sinha S, Hoshino D, Hong NH, Kirkbride KC, Grega-Larson NE, Seiki M, Tyuka Mj, Weaver AM. Cortactin promotes exosome secretion by controlling branched actin dynamics. J Cell Biol. 2016;212(4):197–213.

53. Ostrowski M, Carro N, Krumenich S, Fanger I, Raposo G, Savina A, Moita C, Schlaepfer IR, Nambiar DK, Ramteke A, Kumar R, Dhar D, Agarwal C, Mateen S, Somasagara R, Hussain A, Graner E, Raposo G. The tetraspanin CD63 regulates ESCRT-independent and -dependent extracellular vesicles. Nat Rev Mol Cell Biol. 2018;19(4):213–29.

54. Ostrowski M, Carmo N, Krumeich S, Fanget I, Raposo G, Savina A, Moita C, Overmiller AM, Pierluissi JA, Weinert PJ, Sauma S, Martinez-Outschoorn U, Tulek M, Luginbühl A, Cury J, Harshyne LA, Wahl JK 3rd, et al. Desmoglein 2 modulates extracellular vesicle release from squamous cell carcinoma keratinocytes. FASEB J. 2017;31(18):3412–24.

55. Brennan D, Pettonen S, Dowling A, Medhat W, Green KJ, Wahl JK 3rd, Del Galdo F, Mahoney MG. A role for caveolin-1 in desmoglein binding and desmosome dynamics. Oncogene. 2012;31(13):1636–48.

56. Vered M, Lehtonen M, Hotakainen L, Pihila E, Teppo S, Nyberg P, Sormunen R, Zlotogorski-Hurvitz A, Salo T, Dayan D. Caveolin-1 accumulation in the tongue cancer tumor microenvironment is significantly associated with poor prognosis: an in vivo and in vitro study. BMC Cancer. 2015;15:252.

57. Hadavand M, Haini S. Exosomal biomarkers in oral diseases. Oral Dis. 2019;25:10–5.

58. Loussada-Fernandez F, Rapado-Gonzalez O, Lopez-Cedrun JL, Lopez-More R, Muñoz-Romay L, Suarez-Cunqueiro MM. Liquid Biopsy in Oral Cancer. Int J Mol Sci. 2018;19(6):1704.

59. Ostenfeld M, Jeppe D, Lauberg J, Boysen A, Bramsen J, Priandal-Bengtsson E, Anderson A, Jervis-Dunque J, Sormunen R, Mutschelknaus L, Peters C, Winkler K, Yentrapalli R, Heider T, Atkinson MJ, Seidenfeld J, Hafler T, Atkinson MJ, Peters C, Winkler K, Yentrapalli R, Heider T, Atkinson MJ. Radiation alters the cargo of oral squamous cell carcinoma. Sci Rep. 2016;6:36370.

60. Kawakubo-Yasukochi T, Moroiza H, Hasekawa M, Yasukochi A, Nishinakagawa T, Ono K, Kawasso S, Nakamura N, Nakashima M, Miura-200c-3p spreads invasive capacity in human oral squamous cell carcinoma microenvironment. Mol Carcinog. 2018;57(7):295–302.

61. Dickman C, Lawson J, Jabblee J, Macfellan S, LePard N, Bennetworth G, Garris C. Selective extracellular vesicle exclusion of miR-142-3p by oral cancer cells promotes both internal and extracellular malignant phenotypes. Oncotarget. 2017;8(9):15252–66.

62. Ostenfeld M, Jeppesen D, Laurberg J, Boysen A, Bramsen J, Priandal-Bengtsson E, Anderson A, Jervis-Dunque J, Sormunen R, Mutschelknaus L, Peters C, Winkler K, Yentrapalli R, Heider T, Atkinson MJ, Seidenfeld J, Hafler T, Atkinson MJ, Peters C, Winkler K, Yentrapalli R, Heider T, Atkinson MJ. Radiation alters the cargo of oral squamous cell carcinoma. Sci Rep. 2016;6:36370.
exosomes released from squamous head and neck cancer cells to promote migration of recipient cells. Sci Rep. 2017;7(1):12423.

92. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1991;325(2):186–92.

93. Cook KW, Figg WD. Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin. 2010;60(4):222–43.

94. Todorova D, Simoncini S, Lacroix R, Sabatier F, Dignat-George F. Extracellular Vesicles in Angiogenesis. Curr Res. 2017;120(10):1688–73.

95. Gu M, Li L, Zhang Z, Chen J, Zhang H, Han L, Tang M, You B, Zhang Q, et al. pKRFB3 promotes proliferation, migration and angiogenesis in nasopharyngeal carcinoma. J Cancer. 2017;8(18):3887–96.

96. Xiao H, Feng Y, Tao Y, Zhao P, Shang W, Song K. Microvesicles releasing by oral cancer cells enhance endothelial cell angiogenesis via Shh/RhoA signaling pathway. Cancer Biol Ther. 2017;18(10):783–91.

97. Bao L, You B, Shi S, Shan Y, Zhang Q, Yue H, Zhang J, Zhang W, Shi Y, Liu Y, et al. Metastasis-associated miR-23a from nasopharyngeal carcinoma-derived exosomes mediates angiogenesis by repressing a novel target gene TSGA10. Oncogene. 2018;37(21):2873–89.

98. Chan YK, Zhang H, Liu P, Tiao SW, Lung ML, Mak NK, Ngok-Shun Wong R, Ying-Kit Yue P. Proteomic analysis of exosomes from nasopharyngeal carcinoma cell identifies intercellular transfer of angiogenic proteins. Int J Cancer. 2015;137(8):1830–41.

99. Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2005;5(4):343–54.

100. Théry C, Ostrowski M, Segura E. Membrane vesicles as conveyors of biological information. Nat Rev Mol Cell Biol. 2006;7(6):581–90.

101. Gao L, Wang L, Dai T, Jin K, Zhang Z, Wang S, Xie F, Fang P, Yang B, et al. Metabolic reprogramming: the emerging concept and clinical implications. Metabolism. 2017;78:9–25.

102. Yoshida GJ. Metabolic reprogramming: the emerging concept and clinical implications. Metabolism. 2017;78:9–25.

103. Gu M, Li L, Zhang Z, Chen J, Zhang W, Huang H, et al. Tumor-derived exosomes antagonize innate antiviral immunity. Nat Immunol. 2019;20(3):233–45.

104. Théry C, Ostrowski M, Segura E. Membrane vesicles as conveyors of biological information. Nat Rev Mol Cell Biol. 2006;7(6):581–90.

105. Webber JP, Spary LK, Sanders AJ, Chowdhury R, Jiang WG, Steadman R, Mason MD, Tabi Z, Clayton A. Cancer exosomes regulate expression of immune function-related genes in human immune cells. Flow Cytom Immunofluoresc. 2013;2013:367281.

106. Théry C, Ostrowski M, Segura E. Membrane vesicles as conveyors of biological information. Nat Rev Mol Cell Biol. 2006;7(6):581–90.

107. Whitehead TL. Immune modulation of T-cell and NK (natural killer) cell activities by TEs (tumour-derived exosomes). Biochem Soc Trans. 2013;41(1):245–51.

108. Muller L, Mitsubashi M, Simms P, Gooding WE, Whiteside TL. Tumor-derived exosomes regulate expression of immune-related function genes in human T cell subsets. Sci Rep. 2016;6:20254.

109. Maybruck BT, Pflanzstiel LW, Diaz-Montero M, Gastman BR. Tumor-derived exosomes induce CD8+ T cell suppressors. J Immunother Cancer. 2017;5(1):65.

110. Ye S, Zhang H, Cai T, Liu Y, Ni J, He J, Peng J, Chen Q, Mo H, Jun-Cui n et al: Exosomal miR-24-3p impede T-cell function by targeting TGFβ11 and serves as a potential prognostic biomarker for nasopharyngeal carcinoma. J Pathol. 2016;240(3):329–40.

111. Wiekowski EU, Visus C, Sajnki M, Szczepanski MJ, Storkus WJ, Whiteside TL. Tumor-derived microvesicles promote regulatory T cell expansion and induce apoptosis in tumor-reactive activated CD8+ T lymphocytes. J Immunol. 2009;183(6):3720–30.

112. Kim JW, Wiekowski E, Taylor DO, Reichert TE, Watkins S, Whiteside TL. Fas ligand-positive membrane vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. Clin Cancer Res. 2005;11(3):1010–20.

113. Ye S, Li Z, Luo D, Huang B, Chen Y, Zhang X, Cui J, Zeng Y, Li J, et al. Tumor-derived exosomes promote tumor progression and T-cell dysfunction through the regulation of enriched exosomal microRNAs in human nasopharyngeal carcinoma. Oncotarget. 2014;5(15):5439–52.

114. Mrzljak D, Martin N, Barjon C, Jimenez-Paihes A, Mustapha R, Niki T, Guiyat J, Pancrèt V, de Lauront Y, Busson P, et al. Effect of nasopharyngeal carcinoma-derived exosomes on human regulatory T cells. J Natl Cancer Inst. 2015;107(1):363.
137. Langenm S, Kuhnell I, Parny T, Besiai J, Huang S, Wise-Draper T, Casper K, Zhang X, Medvedovic M, Kasper S. Comprehensive microRNA-sequencing of exosomes derived from head and neck carcinoma cells reveals common secretion profiles and potential utility as salivary biomarkers. Oncotarget. 2017;8(7):82459–74.

138. Sivasasan P, Gupta MK, Sathe GJ, Balakrishnan L, Pal P, Govda H, Suresh A, Kurikose MA, Riteshmukh R. Human salivary proteome—a resource of potential biomarkers for oral cancer. J Proteomics. 2015;127:89–95.

139. Momen-Heravi F, Trachtenberg AJ, Kuo WP, Cheng YS. Genomewide Study of Salivary MicroRNAs for Detection of Oral Cancer. J Dent Res. 2014;93(7 Suppl):895–95.

140. Oga Y, Iwasa Y, Hara-zono M, Kanai-Azuma M, Akimoto Y, Kawakami H, Xie et al. Molecular Cancer (2019) 18:83

141. Rabionovits G, Bowdenn M, Flores LM, Verselis S, Vergara V, Jo VY, Chau N, Lorc J, Hammmerman PS, Thomas T, et al. Proteomic analysis of two types of exosomes in human whole saliva. Biol Pharm Bull. 2011;34(1):13–23.

142. Reclusa P, Taverna S, Pucci M, Durendez E, Calabuig S, Manca P, Serrano MJ, Katsiougiannis S, Chia D, Kim Y, Singh R, Wong D. Saliva exosomes from pancreatic-tumor-bearing mice modulate NK cell phenotype and antitumor cytotoxicity. FASEB J. 2017;31(3):998–1010.

143. Schires P, Taverna S, Pucci M, Durendez E, Calabuig S, Manca P, Serrano MJ, Sober I, Pauwells R, Russo A, et al. Exosomes as diagnostic and predictive biomarkers in lung cancer. J Thorac Dis. 2017;9(Suppl 13):S1373–82.

144. Lau CS, Wong DT. Breast cancer exosome-like microvesicles and salivary gland cells interplay alters salivary gland cell-derived exosome-like microvesicles in vitro. PLoS One. 2012;7(3):e33037.

145. Sharma S, Gillespie BM, Palanisamy V, Gimzewski JK. Quantitative nanostructural and single-molecule force spectroscopy biomolecular analysis of human-saliva-derived exosomes. Langmuir. 2011;27(23):14394–400.

146. Palanisamy V, Sharma S, Deshpande A, Zhou H, Gimzewski J, Wong DT. Nanostructural and transcriptomic analyses of human saliva-derived exosomes. PLoS One. 2010;5(1):e8577.

147. Zlotogorski-Hurvitz A, Dayan D, Chausguh S, Saito T, Verez M. Morphological and molecular features of oral fluid-derived exosomes: oral cancer patients versus healthy individuals. J Cancer Res Clin Oncol. 2016;142(1):101–10.

148. Wilczk F, Prado Ribeiro AC, Ramos Domingues R, Macska L, Pachon DM, Rivara C, Brandao TB, Gouvea AF, Santos-Silva AR, Coletta RD, et al. Insights into immune responses in oral cancer through proteomic analysis of saliva and salivary extracellular vesicles. Sci Rep. 2015;5:16305.

149. Gai C, Camussi F, Broccoletti R, Gambino A, Cabras M, Molinaro L, Carossa S, Camussi G, Arduino PG. Salivary extracellular vesicle-associated miRNAs as potential biomarkers in oral squamous cell carcinoma. BMC Cancer. 2018;18(1):439.

150. Wang J, Zhou Y, Lu J, Sun Y, Xiao H, Liu M, Tian L. Combined detection of serum exosomal miR-21 and HOTAI as diagnostic and prognostic biomarkers for laryngeal squamous cell carcinoma. Med Oncol. 2016;35(1):42.

151. Wang X, Kaczor-Urbanowicz KE, Wong DT. Salivary biomarkers in cancer detection. Med Oncol. 2017;34(1):7.

152. Ren JC, Man QW, Zhang W, Li C, Xiong XP, Zhu JY, Wang WM, Sun ZJ, Jia J, Zhang WF, et al. Elevated Level of Circulating Platelet-derived Microparticles in Oral Cancer. J Dent Res. 2016;95(1):87–93.

153. Wang J, Zhou Y, Lu J, Sun Y, Xiao H, Liu M, Tian L. Combined detection of serum exosomal miR-21 and HOTAI as diagnostic and prognostic biomarkers for laryngeal squamous cell carcinoma. Med Oncol. 2016;35(1):42.

154. Theodoraki MN, Yenneri S, Brunner C, Theodorakis J, Hoffmann TK, Whiteside TL. Plasma-derived Exosomes Reverse Epithelial-to-Mesenchymal Transition after Photodynamic Therapy of Patients with Head and Neck Cancer. Oncoscience. 2018;5(3–4):75–87.

155. Ludwig S, Flores T, Theodoraki MN, Hong CS, Jackson EK, Lang S, Whiteside TL. Suppression of Lymphocyte Functions by Plasma Exosomes Correlates with Disease Activity in Patients with Head and Neck Cancer. Clin Cancer Res. 2017;23(16):4843–54.

156. Andaloussi SE, Mäger I, Breakefield XO, Wood MJA. Extracellular vesicles - new tool for joint repair and regeneration. Nat Rev Rheumatol. 2011;6:243–9.

157. Campos JH, Soares RP, Ribeiro K, Andrade AC, Batista WL, Torrecillas AC. Extracellular Vesicles: Role in Inflammatory Responses and Potential Uses in Cancer and Infectious Diseases. J Immunol Res. 2015;2015:823057.

158. Chen G, Huang AC, Zhang W, Zhang G, Wu M, Xu W, Yu Z, Yang J, Wang B, Sun H, et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature. 2018;560(7718):382–6.

159. Malda J, Boere J, van de Lest CH, van Weeren P, Wauben MH. Extracellular vesicles - new tool for joint repair and regeneration. Nat Rev Rheumatol. 2011;6:243–9.